Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04730973
Other study ID # 2020-005663-31
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date March 1, 2021
Est. completion date March 31, 2022

Study information

Verified date July 2021
Source Azienda Ospedaliera Ordine Mauriziano di Torino
Contact Tiziana Claudia Aranzulla, MD
Phone +390115085038
Email taranzulla@mauriziano.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The CARUSO trial aims at investigating the efficacy of evolocumab in promoting carotid plaque morphological stabilization and regression as compared to traditional lipid lowering therapy (LLT). Primary end-point of the study is the superiority of evolocumab on top of ongoing LLT versus ongoing LLT in carotid plaque morphological stabilization and regression at 6 and 12 months, respectively. Secondary end-points are: LDL-Cholesterol (LDL-C) absolute and percentage changes in the two groups at 12 month follow-up, and adverse cerebrovascular and cardiac events at 12 and 24 months


Description:

Optimal lipid-lowering therapy (LLT) is a mainstay for the therapeutic management of atherosclerotic vascular disease. Cardiac and cerebrovascular adverse events and progression of atherosclerosis are, indeed, reduced in proportion to the achieved LDL cholesterol (LDL-C) levels.In addition, regression of atherosclerotic plaques with optimal LLT has been observed. However, optimal LLT with statin and ezetimibe, might be limited by the onset of adverse effects (i.e. disabling myalgias, diarrhea) with are usually dose -dependent, and the maximum tolerated statin dose might be insufficient to reach the recommended LDL-C goals. The advent of proprotein convertase subtilisin kexin type 9 inhibitors (PCSK9i) has allowed the achievement of very low LDL-C levels, and the fulfillment of the recommended LDL-C targets. However, while the experience with PCSK9i in patients with coronary artery disease has been wide, and coronary plaque regression has been documented, little is known regarding carotid plaque regression following therapy with PCSK9i. Only a few case reports have been published, and no observational study has been carried out so far. Furthermore, morphological carotid plaque stabilization has a prognostic role, and the possibility of its early achievement with PCSK9i may be relevant, especially in the context of percutaneous or surgical carotid interventions.


Recruitment information / eligibility

Status Recruiting
Enrollment 130
Est. completion date March 31, 2022
Est. primary completion date March 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: asymptomatic patients with uni- or bilateral carotid artery stenosis =50% and LDL-C values =100 mg/dL despite ongoing lipid lowering therapy Exclusion Criteria: - age <18 or =81 years old - known intolerance to evolocumab - ongoing or previous treatment with PCSK9i - prior stroke or transient ischemic attack - total carotid occlusion - major active infection or major hematologic, renal, hepatic, or endocrine dysfunction - malignancy with life expectancy below 24 months - failure to sign informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Evolocumab
Evolocumab 140 mg s.c. every two weeks on top of optimal lipid lowering therapy
Other:
lipid-lowering therapy (LLT)
lipid-lowering therapy (LLT)

Locations

Country Name City State
Italy Azienda Ospedaliera Ordine Mauriziano di Torino Torino Piedmont

Sponsors (1)

Lead Sponsor Collaborator
Azienda Ospedaliera Ordine Mauriziano di Torino

Country where clinical trial is conducted

Italy, 

References & Publications (1)

Aranzulla TC, Piazza S, Ricotti A, Musumeci G, Gaggiano A. CARotid plaqUe StabilizatiOn and regression with evolocumab: Rationale and design of the CARUSO study. Catheter Cardiovasc Interv. 2021 Jul 1;98(1):E115-E121. doi: 10.1002/ccd.29743. Epub 2021 Apr — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Morphological carotid plaque stabilization Morphological stabilization of the carotid plaque evaluated with Carotid duplex ultra-sonography Six months
Primary Carotid plaque regression Carotid plaque regression evaluated with Carotid duplex ultra-sonography and defined as reduction of the entity of the stenosis and/or peak systolic velocity by at least 5%, as compared to baseline. 12 months
Secondary Changes of LDL-C Absolute changes of LDL-C 12 months
Secondary Major adverse cerebrovascular events All-cause mortality, cardiovascular mortality, stroke, myocardial infarction, any coronary or peripheral revascularization 12 and 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT02124928 - Morphological and Serological Criteria of Plaque Vulnerability: Risk Assessment for Symptomatic and Asymptomatic Carotid Artery Stenosis N/A
Active, not recruiting NCT01597453 - NOR-SYS: The Norwegian Stroke in the Young Study N/A
Completed NCT00744523 - Proximal Protection With The Mo.Ma Device During Carotid Stenting N/A
Completed NCT00231231 - Carotid Artery Stenting With Emboli Protection Surveillance-Post-Marketing Study (CASES-PMS) Phase 3
Completed NCT00597974 - Neurological Outcome With Carotid Artery Stenting N/A
Completed NCT00587717 - The Acute Effect of Statins on Inflammatory Markers of Athersclerotic Tissue N/A
Completed NCT02536378 - POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE
Completed NCT02126982 - Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence
Active, not recruiting NCT01445613 - Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy N/A
Terminated NCT01414387 - Effects of Cerebral Protection With Filters vs. Flow Reversal on Cerebral Embolization After Carotid Artery Stenting N/A
Completed NCT00406055 - CHOICE: Carotid Stenting For High Surgical-Risk Patients Phase 4
Completed NCT00403078 - SAPPHIRE Worldwide: Stenting and Angioplasty With Protection in Patients At High-Risk for Endarterectomy
Terminated NCT01968226 - TRACER RGD-K5 Carotid Plaque Imaging Study Phase 2
Completed NCT01685567 - Safety and Efficacy Study for Reverse Flow Used During Carotid Artery Stenting Procedure Phase 3
Completed NCT00402740 - Protected Carotid Artery Stenting in Subjects at High Risk for Carotid Endarterectomy (CEA) (PROTECT) N/A
Completed NCT00287508 - Emboshield® and Xact® Post Approval Carotid Stent Trial (The EXACT Study) Phase 4
Completed NCT00178672 - A Single Center of Carotid Stenting With Distal Protection for the Treatment of Obstructive Carotid Artery Disease Phase 4
Recruiting NCT02850588 - SVS VQI TransCarotid Revascularization Surveillance Project
Completed NCT02759653 - Norwegian Carotid Plaque Study
Withdrawn NCT01042912 - Frequency Analysis of Carotid Artery Disease N/A